Tema Oncology ETFCANC
Type
ETF
Peer group
Global equity
Net assets
$159.9M
Expense ratio
0.75%
1-year return
+62.9%
3 years, a year
+21.3%
5 years, a year
—
12-month yield
0.05%
Holdings
56
What it aims to do.
Tema Oncology ETF (the Fund) seeks to provide long-term growth.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| RVMD Revolution Medicines Inc | 6.29% |
| Novartis AG | 4.96% |
| BBIO Bridgebio Pharma Inc | 4.75% |
| AstraZeneca PLC | 4.63% |
| LLY Eli Lilly & Co | 4.32% |
| BMY Bristol-Myers Squibb Co | 4.22% |
| Roche Holding AG | 4.06% |
| MRK Merck & Co Inc | 3.84% |
| Arcellx Inc | 3.44% |
| COGT Cogent Biosciences Inc | 3.29% |
More on CANC.
- CANC overview
- CANC holdings
- CANC risk
- CANC costs
- CANC money in and out
- CANC share classes
- Compare CANC with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.